233 related articles for article (PubMed ID: 25393910)
1. The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease.
Patton JT; Lustberg ME; Lozanski G; Garman SL; Towns WH; Drohan CM; Lehman A; Zhang X; Bolon B; Pan L; Kinghorn AD; Grever MR; Lucas DM; Baiocchi RA
Oncotarget; 2015 Feb; 6(5):2693-708. PubMed ID: 25393910
[TBL] [Abstract][Full Text] [Related]
2. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus-specific T-cell cytotoxicity is mediated through the perforin pathway in patients with lymphoproliferative disorders after allogeneic bone marrow transplantation.
Yoshimi A; Tsuge I; Namizaki H; Hoshino Y; Kimura H; Takahashi Y; Watanabe N; Kuzushima K; Kojima S
Br J Haematol; 2002 Mar; 116(3):710-5. PubMed ID: 11849237
[TBL] [Abstract][Full Text] [Related]
4. T cell repertoire and Epstein-Barr virus-specific T cell response in chronic active Epstein-Barr virus infection: a case study.
Gallot G; Hamidou MA; Clémenceau B; Gaschet J; Tiberghien P; Ferrand C; Vivien R; Barbarot S; Coste-Burel M; Moreau A; Vié H
Clin Immunol; 2006 Apr; 119(1):79-86. PubMed ID: 16386957
[TBL] [Abstract][Full Text] [Related]
5. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
6. The role of virus-specific CD4+ T cells in the control of Epstein-Barr virus infection.
Mautner J; Bornkamm GW
Eur J Cell Biol; 2012 Jan; 91(1):31-5. PubMed ID: 21458882
[TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.
Albanese M; Tagawa T; Bouvet M; Maliqi L; Lutter D; Hoser J; Hastreiter M; Hayes M; Sugden B; Martin L; Moosmann A; Hammerschmidt W
Proc Natl Acad Sci U S A; 2016 Oct; 113(42):E6467-E6475. PubMed ID: 27698133
[TBL] [Abstract][Full Text] [Related]
8. Regulation of human cell engraftment and development of EBV-related lymphoproliferative disorders in Hu-PBL-scid mice.
Wagar EJ; Cromwell MA; Shultz LD; Woda BA; Sullivan JL; Hesselton RM; Greiner DL
J Immunol; 2000 Jul; 165(1):518-27. PubMed ID: 10861091
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus, rapamycin, and host immune responses.
Krams SM; Martinez OM
Curr Opin Organ Transplant; 2008 Dec; 13(6):563-8. PubMed ID: 19060543
[TBL] [Abstract][Full Text] [Related]
10. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
[TBL] [Abstract][Full Text] [Related]
11. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases.
Kanazawa T; Hiramatsu Y; Iwata S; Siddiquey M; Sato Y; Suzuki M; Ito Y; Goshima F; Murata T; Kimura H
Clin Cancer Res; 2014 Oct; 20(19):5075-84. PubMed ID: 25117294
[TBL] [Abstract][Full Text] [Related]
12. CD8(+) T-cell lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis during methotrexate therapy.
Hatachi S; Kunitomi A; Aozasa K; Yagita M
Mod Rheumatol; 2010 Oct; 20(5):500-5. PubMed ID: 20437072
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
14. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness ME; Kenney JL; Reiss M; Lacy J
Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
[TBL] [Abstract][Full Text] [Related]
15. Virus-specific cytotoxic CD4+ T cells for the treatment of EBV-related tumors.
Merlo A; Turrini R; Bobisse S; Zamarchi R; Alaggio R; Dolcetti R; Mautner J; Zanovello P; Amadori A; Rosato A
J Immunol; 2010 May; 184(10):5895-902. PubMed ID: 20385879
[TBL] [Abstract][Full Text] [Related]
16. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
17. Clonal origin of Epstein-Barr virus (EBV)-infected T/NK-cell subpopulations in EBV-positive T/NK-cell lymphoproliferative disorders of childhood.
Ohga S; Ishimura M; Yoshimoto G; Miyamoto T; Takada H; Tanaka T; Ohshima K; Ogawa Y; Imadome K; Abe Y; Akashi K; Hara T
J Clin Virol; 2011 May; 51(1):31-7. PubMed ID: 21377409
[TBL] [Abstract][Full Text] [Related]
18. Gene-corrected human Munc13-4-deficient CD8+ T cells can efficiently restrict EBV-driven lymphoproliferation in immunodeficient mice.
Soheili T; Rivière J; Ricciardelli I; Durand A; Verhoeyen E; Derrien AC; Lagresle-Peyrou C; de Saint Basile G; Cosset FL; Amrolia P; André-Schmutz I; Cavazzana M
Blood; 2016 Dec; 128(24):2859-2862. PubMed ID: 27799161
[No Abstract] [Full Text] [Related]
19. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
[TBL] [Abstract][Full Text] [Related]
20. Immune Evasion by Epstein-Barr Virus.
Ressing ME; van Gent M; Gram AM; Hooykaas MJ; Piersma SJ; Wiertz EJ
Curr Top Microbiol Immunol; 2015; 391():355-81. PubMed ID: 26428381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]